First and only PARP inhibitor to improve overall survival in early breast cancer
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
The product will be manufactured at Lupin’s Somerset facility in the US
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
